EdgeMarket › What Siren, L.L.C. reported owning
What Siren, L.L.C. reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
3.6BPositions
100Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| SRRK Scholar Rock Holding Corp | 532.2M | 14.8% | 10.8M | 56.50 | +64.2% |
| KYMR Kymera Therapeutics, Inc. | 265.4M | 7.4% | 3.2M | 119.80 | +182.9% |
| ERAS Erasca, Inc. | 181.9M | 5.0% | 11.2M | 17.63 | +1107.5% |
| EWTX Edgewise Therapeutics, Inc. | 139.6M | 3.9% | 4.4M | 44.18 | +219.2% |
| ONC BeOne Medicines Ltd. | 138.1M | 3.8% | 465.0K | 374.47 | +21.1% |
| TNGX Tango Therapeutics, Inc. | 118.3M | 3.3% | 5.7M | 23.88 | +253.8% |
| BCAX Bicara Therapeutics Inc. | 115.4M | 3.2% | 5.8M | 23.90 | +118.1% |
| RVMD Revolution Medicines, Inc. | 108.0M | 3.0% | 1.1M | 209.46 | +479.3% |
| ARWR ARROWHEAD PHARMACEUTICALS, INC. | 101.3M | 2.8% | 1.6M | 87.11 | +331.2% |
| MANE Veradermics, Inc | 95.1M | 2.6% | 1.5M | 102.82 | — |
| XENE Xenon Pharmaceuticals Inc. | 76.7M | 2.1% | 1.3M | 60.77 | +61.5% |
| OLMA Olema Pharmaceuticals, Inc. | 70.9M | 2.0% | 4.8M | 10.69 | +96.1% |
| CRNX Crinetics Pharmaceuticals, Inc. | 69.1M | 1.9% | 1.9M | 84.69 | +191.1% |
| LXRX LEXICON PHARMACEUTICALS, INC. | 69.1M | 1.9% | 44.3M | 2.30 | +103.5% |
| COGT Cogent Biosciences, Inc. | 65.8M | 1.8% | 1.7M | 36.73 | +209.6% |
| STOK Stoke Therapeutics, Inc. | 65.0M | 1.8% | 2.0M | 32.29 | +67.1% |
| RCUS Arcus Biosciences, Inc. | 65.0M | 1.8% | 3.0M | 30.34 | +200.7% |
| GPCR Structure Therapeutics Inc. | 64.0M | 1.8% | 1.3M | 49.09 | +164.4% |
| IRON Disc Medicine, Inc. | 63.2M | 1.8% | 988.4K | 79.81 | +35.9% |
| RYTM RHYTHM PHARMACEUTICALS, INC. | 63.1M | 1.7% | 725.5K | 110.00 | +11.4% |
| SLDB Solid Biosciences Inc. | 55.4M | 1.5% | 7.7M | 9.30 | +64.3% |
| SEPN Septerna, Inc. | 48.1M | 1.3% | 2.0M | 40.00 | +260.7% |
| unmapped CUSIP 152309100 | 41.8M | 1.2% | 1.1M | — | — |
| SYRE Spyre Therapeutics, Inc. | 41.3M | 1.1% | 818.6K | 106.49 | +551.3% |
| CYTK CYTOKINETICS INC | 40.5M | 1.1% | 614.0K | 76.84 | +105.9% |
| DYN Dyne Therapeutics, Inc. | 40.4M | 1.1% | 2.2M | 26.10 | +118.0% |
| TSHA Taysha Gene Therapies, Inc. | 39.5M | 1.1% | 8.8M | 6.09 | +112.2% |
| DBVT DBV Technologies S.A. | 38.8M | 1.1% | 1.9M | 14.55 | +48.5% |
| ORIC Oric Pharmaceuticals, Inc. | 38.0M | 1.1% | 3.0M | 14.20 | +49.3% |
| ENGN enGene Therapeutics Inc. | 35.8M | 1.0% | 5.3M | 1.78 | -53.9% |
| PVLA PALVELLA THERAPEUTICS, INC. | 32.1M | 0.9% | 257.5K | 142.04 | +181.6% |
| TBLA Taboola.com Ltd. | 30.9M | 0.9% | 10.0M | 3.73 | +15.1% |
| ELVN Enliven Therapeutics, Inc. | 29.3M | 0.8% | 746.2K | 59.82 | +204.3% |
| DNLI Denali Therapeutics Inc. | 26.8M | 0.7% | 1.4M | 24.92 | +71.7% |
| RELY Remitly Global, Inc. | 24.2M | 0.7% | 1.5M | 26.67 | +41.6% |
| DMRA Damora Therapeutics, Inc. | 23.3M | 0.6% | 900.0K | 30.82 | +811.9% |
| ZURA Zura Bio Ltd | 22.2M | 0.6% | 3.7M | 5.85 | +234.3% |
| ANNX Annexon, Inc. | 21.9M | 0.6% | 4.0M | 5.07 | +136.9% |
| TRVI Trevi Therapeutics, Inc. | 21.3M | 0.6% | 1.8M | 17.96 | +142.0% |
| RAPP Rapport Therapeutics, Inc. | 20.1M | 0.6% | 641.5K | 48.24 | +236.9% |
| GOOGL Alphabet Inc. | 18.9M | 0.5% | 65.7K | 344.82 | +73.0% |
| FULC Fulcrum Therapeutics, Inc. | 18.0M | 0.5% | 2.4M | 3.83 | -41.7% |
| WVE Wave Life Sciences, Inc. | 17.8M | 0.5% | 2.5M | 5.29 | -44.0% |
| DFTX Definium Therapeutics, Inc. | 17.4M | 0.5% | 919.5K | 44.91 | +375.2% |
| AMLX Amylyx Pharmaceuticals, Inc. | 17.1M | 0.5% | 1.2M | 38.66 | +381.4% |
| CGEM Cullinan Therapeutics, Inc. | 17.0M | 0.5% | 1.2M | 21.68 | +190.2% |
| NMRA Neumora Therapeutics, Inc. | 16.6M | 0.5% | 8.5M | 1.63 | +1.2% |
| QURE uniQure N.V. | 16.4M | 0.5% | 1.0M | 48.37 | +212.5% |
| CTMX CytomX Therapeutics, Inc. | 16.3M | 0.5% | 3.5M | 3.28 | +66.5% |
| NVDA NVIDIA CORP | 15.5M | 0.4% | 89.1K | 214.72 | +22.4% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →